Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.5950
-0.0150 (-2.46%)
Jun 3, 2026, 2:52 PM EDT - Market open
Company Description
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States.
Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury.
The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida.
Oragenics, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Janet Huffman |
Contact Details
Address: 9015 Town Center Parkway, Suite 143 Lakewood Ranch, Florida 34202 United States | |
| Phone | 813 286 7900 |
| Website | oragenics.com |
Stock Details
| Ticker Symbol | OGEN |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001174940 |
| CUSIP Number | 684023609 |
| ISIN Number | US6840236094 |
| Employer ID | 59-3410522 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Janet Huffman | Chief Executive Officer, President, Chief Financial Officer, Secretary and Treasurer |
| Dr. James P. Kelly M.A., M.D. | Chief Medical Officer |
| Dr. William Franklin Peacock IV, F.A.C.E.P., FACC, M.D. | Chief Clinical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 20, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 20, 2026 | DEF 14A | Other definitive proxy statements |
| May 19, 2026 | 8-K | Current Report |
| May 8, 2026 | PRE 14A | Other preliminary proxy statements |
| May 8, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| Apr 13, 2026 | 8-K | Current Report |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 20, 2026 | EFFECT | Notice of Effectiveness |
| Mar 19, 2026 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |